| ORIGINAL ARTICLE |
|
| Year : 2019 | Volume
: 44
| Issue : 4 | Page : 195-203 |
|
|
Study of Wilms’ tumor 1 gene expression in patients with acute myeloid leukemia
Ebtesam I Ahmad1, Ghada M El-Akad1, Weaam I Ismail MSc 1, Ahmed A.R Al Nagar2
1 Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Correspondence Address:
Weaam I Ismail
Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig 44159, Egypt. Tel: 00201223140501;
Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ejh.ejh_26_19
|
|
|
Background The Wilms’ tumor 1 (WT1) gene is overexpressed in patients with acute leukemias. Many studies have reported the importance of quantitative assessment of WT1 expression as a molecular marker of minimal residual disease monitoring. However, biological significance and the prognostic effect of WT1 overexpression in acute myeloid leukemia (AML) remain elusive.
Subjects and methods A total of 42 patients with newly diagnosed AML were included in the study. Also, 42 individuals matched for age and sex were enrolled as controls. Immunophenotyping, cytogenetic analysis, and quantitative assessment of WT1 gene transcripts were performed using real-time PCR.
Results WT1 overexpression was detected in 73.8% of our patient group. There was a statistically significant decrease in the probability of achieving complete remission with shorter overall survival and event-free survival in the WT1 overexpression group compared with the downexpression group (P=0.035, 0.045, 0.011, respectively). Application of multivariate analysis showed that WT1 overexpression by itself is an independent and negative indicator for predicting overall survival and disease-free survival of AML patients.
Conclusion WT1 overexpression is an independent negative prognostic marker that could be used to evaluate response to induction chemotherapy and prognosis of AML patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
